title: Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
authors.forename: Sunanda
authors.initials: S
authors.lastname: Kane
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000493:pharmacokinetics*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D044967:Serum / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol